Table 1.
Characteristics of Male Patients with Advanced Cancer
| Patient characteristics | N=119 (%)1 |
|---|---|
| Mean Age (years), range | 61 (31–91) |
| Male sex | 119 (100) |
| Race | |
| White | 85 (71) |
| Black | 13 (11) |
| Hispanic | 11 (9) |
| Asian | 10 (8) |
| Cancer Diagnosis | |
| Gastrointestinal | 48 (40) |
| Genitourinary | 10 (8) |
| Hematological | 3 (3) |
| Head & Neck | 18 (15) |
| Lung | 30 (25) |
| Other | 10 (8) |
| Median weight loss % in last 6 months, (Q1-Q3) | 7.0 (3.2–12.9) |
| Weight loss >5% in last 6 months | 72 (62) |
| Median 25OH Vitamin D level (ng/mL), (Q1-Q3) | 21 (13–31) |
| Median TSH (mcU/mL), (Q1-Q3) | 2 (1–3) |
| Median Total Testosterone (ng/dl), (Q1-Q3) | 209 (98–378) |
| Median Free Testosterone (ng/dl), 2 (Q1-Q3) | 4.4 (1.9–7.5) |
| Median Bio-available Testosterone (ng/dL), 3 (Q1-Q3) | 22.0 (8.1–41.5) |
| Median hs CRP (mg/L), (Q1-Q3) | 33.3 (9.5–91.0) |
| Median WBC (K/UL), (Q1-Q3) | 6.6 (4.6–10.0) |
| Median Hemoglobin (g/dL), median (Q1-Q3) | 11.3 (10.2–12.6) |
| Median Albumin (mg/dL), median (Q1-Q3) | 3.8 (3.3–4.1) |
| Median MEDD (mg/d), median (Q1-Q3) | 30 (0–100) |
| Median Edmonton Symptom Assessment Score, (Q1-Q3) | |
| Pain | 4 (2–6) |
| Fatigue | 5 (3–7) |
| Nausea | 1 (0–2) |
| Depression | 2 (0–3) |
| Anxiety | 2 (0–4) |
| Drowsiness | 3 (1–5) |
| Appetite | 5 (2–7) |
| Well Being | 5 (3–6) |
| Dyspnea | 2 (0–5) |
| Sleep | 4 (2–7) |
| Median Survival (days), 95% CI | 151 (116–186) |
1
unless otherwise specified;
2
N=116;
3
N=118; TSH – thyroid stimulating hormone; hs CRP – high-sensitivity C-reactive protein; WBC – white blood cell count; MEDD – morphine equivalent daily dosing.